Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.
Klebanoff
Christopher A
CA
Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA.
Khong
Hung T
HT
Antony
Paul A
PA
Palmer
Douglas C
DC
Restifo
Nicholas P
NP
D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects / Q000276:immunology* / Q000528:radiation effects; D002986:Clinical Trials as Topic; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D016219:Immunotherapy, Adoptive; D053631:Interleukin Receptor Common gamma Subunit; D007378:Interleukins / Q000276:immunology* / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000276:immunology; D008212:Lymphocyte Depletion; D018448:Models, Immunological; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D020395:Receptors, Interleukin-7 / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D016896:Treatment Outcome
C507941:IL2RG protein, human; D053631:Interleukin Receptor Common gamma Subunit; D007378:Interleukins; D020395:Receptors, Interleukin-7